The Impact of PCSK9 Modulation on Cardiovascular Outcomes in Lipid Management: Recent Advances and Managed Care Considerations

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2023 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 1, 2023 to August 1, 2024

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Novartis Pharmaceuticals Corporation

Over 73 million adults in the United States have hypercholesterolemia and are at elevated risk for atherosclerotic cardiovascular disease. Low-density lipoprotein cholesterol (LDL-C) is a primary mediator of the development of heart disease and plays a key role in determining cardiovascular risk and overall health management. Early and aggressive lowering of LDL-C reduces the risk of atherosclerotic cardiovascular disease (ASCVD) events in patients with hypercholesterolemia, and every 1.0 mmol/L reduction in LDL-C is estimated to lead to ~20% reduction in the relative risk of major cardiovascular events. Statins are the mainstay of hypercholesterolemia management, but many patients do not tolerate statin-based treatment, which ultimately leads to medication nonadherence, ASCVD events, and higher healthcare costs. On the other hand, some patients, including those with pre-existing ASCVD or severe hypercholesterolemia, do not reach recommended LDL-C treatment targets despite intensive statin therapy. Non-statin agents can be useful for patients who inadequately respond to or are intolerant of statin therapy. Fortunately for patients with high LDL-C, several new treatments have recently become available as an adjunct or instead of statin therapies. These options, including agents that inhibit production of PCSK9, have shown improved efficacy and safety, offering patients the potential for improved outcomes and quality of life. With so many new options becoming available in recent years that have shown the ability to lower LDL-C and reduce cardiovascular risk in lipid management, it is critical that physician medical directors, payers, cardiologists, pharmacy directors, pharmacists, nurse case managers, and other HCPs are updated on the comparisons among safety, efficacy, and administration data on these options, possible strategies for implementing them into the treatment paradigm, and key points that managed care professionals need to know, which will ultimately improve both clinical and economic outcomes.

Upon completion of this activity, participants will be able to:

  • Assess the clinical and economic consequences of patient non-adherence and clinical inertia on ASCVD event risk in patients with hypercholesterolemia

  • Recognize the need for the early and adequate intensification of LDL-C lowering therapy beyond statins to address ASCVD risk

  • Examine the clinical data and guideline recommendations for the use of PCSK9-modulating therapies in the treatment of hypercholesterolemia

  • Explore the role of siRNA-based inhibition of PCSK9 in managing patients with hypercholesterolemia or ASCVD

  • Identify patients who may benefit from PCSK9 inhibition in place of or as an adjunct to statin therapy

  • Implement managed care strategies to integrate evidence-based use of PCSK9-modulating therapies while controlling healthcare resource utilization


Faculty: Robert S. Rosenson, MD
Professor of Cardiology and Director of Metabolism and Lipids
Icahn School of Medicine at Mount Sinai


(Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Rosenson has served as a consultant for Amgen, CRISPER, Eli Lilly, Lipigon, Novartis, Precision Biosciences, Regeneron, UltraGenyx, and Verve. He has served as a speaker for Kowa. He has received grant/research support from Amgen, Arrowhead, Eli Lilly, Novartis, and Regeneron. He holds stock in MedImergent, LLC. His presentation has been reviewed for any bias.
Planning Committee: Bill Williams, MD has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jeremy Williams has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Novartis Pharmaceuticals Corporation

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue